Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DL9ZT4
|
|||
| Drug Name |
Utomilumab
|
|||
| Synonyms |
PF-05082566
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Co-stimulatory molecule 4-1BB (CD137) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01307267) A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab. U.S. National Institutes of Health. | |||
| REF 2 | First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.